March 5 (Reuters) - Healius' (HLS) shares jumped more than 11% on Tuesday after the healthcare firm said it would start a review and engage investment advisers after Australia's competition regulator killed the $1 billion takeover by rival Australian Clinical Labs (ACL) last year.
Healius also said Chief Financial Officer Paul Anderson will transition to the CEO role, replacing Maxine Jaquet.
News: ACL Australia's Healius jumps on review, CEO change
Add ACL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.44 |
Change
-0.010(0.41%) |
Mkt cap ! $492.4M | |||
| Open | High | Low | Value | Volume |
| $2.45 | $2.49 | $2.43 | $2.172M | 886.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2650 | $2.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.48 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.45 |
Change
-0.010 ( 0.22 %) |
||||
| Open | High | Low | Volume | ||
| $2.47 | $2.49 | $2.44 | 124278 | ||
| Last updated 15.59pm 16/05/2024 ? | |||||
| ACL (ASX) Chart |